


PHARMACEUTICAL 2022

CTI BIOPHARMA CORP Rank 426 of 475







PHARMACEUTICAL 2022

CTI BIOPHARMA CORP Rank 426 of 475



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 141% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Net Income, reducing the Economic Capital Ratio by 262% points.

The company's Economic Capital Ratio, given in the ranking table, is -558%, being 281% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	68,379
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	66,651
Liabilities, Non-Current	2,016
Other Assets	3,879
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,576
Property and Equipment	176
Research and Development	39,136
Revenues	0
Selling, General and Administrative Expense	56,196

Output Variable	Value in 1000 USD
Assets	72,434
Liabilities	68,667
Expenses	95,332
Stockholders Equity	3,767
Net Income	-97,908
Comprehensive Net Income	-97,909
Economic Capital Ratio	-558%